Bavarian Nordic A/S
COPENHAGEN, Denmark, March 17, 2021 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announces that the Company, as set out in Section 38 in the Danish Capital Markets Act and section 55, cf. 56 of the Danish Companies Act, has received notification from Invesco Ltd confirming that Invesco Ltd., as a result of Bavarian Nordic’s recent capital increase, indirectly holds below 5% of the voting rights in Bavarian Nordic A/S as of March 15, 2021.
The voting rights indirectly controlled by Invesco Ltd. are held by Invesco Advisers, Inc. to which voting right have been delegated by a number of funds managed by affiliates of the Invesco group management companies.
About Bavarian Nordic
Bavarian Nordic is a fully integrated vaccines company focused on the development, manufacture and commercialization of life-saving vaccines. We are a global leader in smallpox vaccines and have been a long-term supplier to the U.S. Strategic National Stockpile of a non-replicating smallpox vaccine, which has been approved by the FDA under the trade name JYNNEOS®, also for the protection against monkeypox. The vaccine is approved as a smallpox vaccine in Europe under the trade name IMVANEX® and in Canada under the trade name IMVAMUNE®. Our commercial product portfolio furthermore contains the market-leading vaccine Rabipur®/RabAvert® against rabies and Encepur® against tick-borne encephalitis. Using our live virus vaccine platform technology, MVA-BN®, we have created a diverse portfolio of proprietary and partnered product candidates designed to save and improve lives by unlocking the power of the immune system, including an Ebola vaccine, MVABEA®, which is licensed to Janssen. For more information visit www.bavarian-nordic.com.
Contacts
Europe: Rolf Sass Sørensen, Vice President Investor Relations, Tel: +45 61 77 47 43
US: Graham Morrell, Paddock Circle Advisors, graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 09 / 2021
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Alvotech4.7.2025 01:02:13 CEST | Press release
Notification for the purposes of article 13 of the Luxembourg law of 11 January 2008 on transparency requirements for issuers
RIB Software3.7.2025 21:17:25 CEST | Press release
RIB Software Recognized as a Leader for Construction Management Software by Independent Research Firm
Solvay S.A.3.7.2025 18:00:00 CEST | Press release
Participation notification by Morgan Stanley
Siili Solutions Oyj3.7.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 3.7.2025
Virtune AB (Publ)3.7.2025 15:29:54 CEST | Press release
Virtune AB (Publ) ("Virtune") has completed the monthly rebalancing for June 2025 of its Virtune Crypto Top 10 Index ETP - the first crypto index ETP in the Nordics
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom